Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引：73

作者：

Boucau, Julie ^{[1
]}

Uddin, Rockib ^{[2
]}

Marino, Caitlin ^{[1
]}

Regan, James ^{[3
]}

Flynn, James P. ^{[3
]}

Choudhary, Manish C. ^{[3
,4
]}

Chen, Geoffrey ^{[2
]}

Stuckwisch, Ashley M. ^{[2
]}

Mathews, Josh ^{[2
]}

Liew, May Y. ^{[2
]}

Singh, Arshdeep ^{[2
]}

Reynolds, Zahra ^{[2
]}

Iyer, Surabhi L. ^{[2
]}

Chamberlin, Grace C. ^{[2
]}

Vyas, Tammy D. ^{[2
]}

Vyas, Jatin M. ^{[2
,4
]}

Turbett, Sarah E. ^{[2
]}

Li, Jonathan Z. ^{[3
,4
]}

Lemieux, Jacob E. ^{[2
,4
,5
]}

Barczak, Amy K. ^{[1
,2
,4
]}

Siedner, Mark J. ^{[2
,4
]}

机构：

[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA

[2] Massachusetts Gen Hosp, Boston, MA 02215 USA

[3] Brigham & Womens Hosp, Boston, MA 02215 USA

[4] Harvard Med Sch, Boston, MA 02215 USA

[5] Broad Inst, Cambridge, MA 02138 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期

关键词：

COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;

D O I：

10.1093/cid/ciac512

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

引用

页码：E526 / E529

页数：4

共 50 条

[21] Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
Zheng, Qian
Ma, Pengfei
Feng, Zhanhui
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2023, 65 : 214 - 215
[22] VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19
Cao, Zhujun
Gao, Weiyi
Bao, Hong
Feng, Haiyan
Mei, Shuya
Chen, Peizhan
Gao, Yueqiu
Cui, Zhilei
Zhang, Qin
Meng, Xianmin
Gui, Honglian
Wang, Weijing
Jiang, Yimei
Song, Zijia
Shi, Yiqing
Sun, Jing
Zhang, Yifei
Xie, Qing
Xu, Yiping
Ning, Guang
Gao, Yuan
Zhao, Ren
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (05): : 406 - 417
[23] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
Cheng, Franco Wing Tak
Yan, Vincent Ka Chun
Wan, Eric Yuk Fai
Chui, Celine Sze Ling
Lai, Francisco Tsz Tsun
Wong, Carlos King Ho
Li, Xue
Zhang, Irene Ran
Tang, Sydney Chi Wai
Wong, Ian Chi Kei
Chan, Esther Wai Yin
KIDNEY INTERNATIONAL REPORTS, 2024, 9 (05): : 1244 - 1253
[24] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19
Focosi, Daniele
Nicastri, Emanuele
ANNALS OF INTERNAL MEDICINE, 2023, 176 (10)
[25] Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
Han, Jaijun
Bae, Seongman
Jung, Jiwon
Kim, Min Jae
Chong, Yong Pil
Lee, Sang-Oh
Choi, Sang-Ho
Kim, Yang Soo
Chang, Euijin
Kim, Sung-Han
MEDICINE, 2023, 102 (39) : E35094
[26] Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
Zhao, Xiang
Cheng, Yuan
Zhang, Meng
Qianda, Bianba
Zhouma, Baima
Yangzhen, Bianba
Zheng, Yao
Zhang, Shuo
Zhao, Huiying
INFECTION AND DRUG RESISTANCE, 2023, 16 : 6053 - 6060
[27] SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy An Observational Study
Edelstein, Gregory E.
Boucau, Julie
Uddin, Rockib
Marino, Caitlin
Liew, May Y.
Barry, Mamadou
Choudhary, Manish C.
Gilbert, Rebecca F.
Reynolds, Zahra
Li, Yijia
Tien, Dessie
Sagar, Shruti
Vyas, Tammy D.
Kawano, Yumeko
Sparks, Jeffrey A.
Hammond, Sarah P.
Wallace, Zachary
Vyas, Jatin M.
Barczak, Amy K.
Lemieux, Jacob E.
Li, Jonathan Z.
Siedner, Mark J.
ANNALS OF INTERNAL MEDICINE, 2023, 176 (12) : 1577 - 1585
[28] Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
Wong, Grace Lai-Hung
Yip, Terry Cheuk-Fung
Lai, Mandy Sze-Man
Wong, Vincent Wai-Sun
Hui, David Shu-Cheong
Lui, Grace Chung-Yan
JAMA NETWORK OPEN, 2022, 5 (12) : e2245086
[29] Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis
Cheema, Huzaifa A. A.
Jafar, Uzair
Sohail, Aruba
Shahid, Abia
Sahra, Syeda
Ehsan, Muhammad
Athar, Farwa
Shah, Jaffer F.
Sah, Ranjit
JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
[30] Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With Coronavirus Disease 2019
Shah, Melisa M.
Joyce, Brendan
Plumb, Ian D.
Sahakian, Sam
Feldstein, Leora R.
Barkley, Eric
Paccione, Mason
Deckert, Joseph
Sandmann, Danessa
Hagen, Melissa Briggs
Gerhart, Jacqueline L.
CLINICAL INFECTIOUS DISEASES, 2024, 79 (01) : 108 - 110

← 1 2 3 4 5 →